UBS analyst Eliana Merle maintained a Hold rating on BioNTech SE (BNTX – Research Report) today and set a price target of $110.00. The company’s shares opened today at $88.93.
According to TipRanks, Merle is an analyst with an average return of -1.7% and a 38.98% success rate. Merle covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Apellis Pharmaceuticals, and BioNTech SE.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioNTech SE with a $117.86 average price target.
See Insiders’ Hot Stocks on TipRanks >>
BNTX market cap is currently $22.11B and has a P/E ratio of 8.08.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioNTech SE (BNTX) Company Description:
BioNTech SE is a Germany-based biotechnology company that develops and manufactures immunotherapies for cancer, infectious diseases, allergies and autoimmune disorders.
Read More on BNTX:
- BioNTech Expects Continued Growth into 2024
- Options Volatility and Implied Earnings Moves Today, March 20, 2024
- BioNTech Welcomes New Chief Commercial Officer
- BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
- Novavax (NASDAQ:NVAX) Remains Highly Speculative, Post-Pandemic
